New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI in 3rd and ... MarketWatch (press release) Compared to physicians' choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 ... |
